Li Gen

Ligen Biopharma is a clinical-stage biotechnology company headquartered in Suzhou, China, specializing in the discovery and development of innovative small molecule drugs and targeted protein degraders. Founded by Dr. Li Gen, a veteran of the pharmaceutical industry with experience at Amgen and Pfizer, the company focuses on high-value targets in oncology and immunology, such as HPK1 and SHP2. Ligen Biopharma leverages its proprietary platforms for Proteolysis Targeting Chimeras (PROTACs) and molecular glues to address previously undruggable targets. The company has successfully raised significant venture capital from prominent investors like Oriza Holdings and Sherpa Healthcare Partners to advance its diverse pipeline. Its lead programs are currently in the pre-clinical and IND-enabling stages, aiming to provide next-generation therapies for patients with unmet medical needs.